Influsplit

Influenza Virus B/Austria/1359417/2021‑Like Strain (B/Austria/1359417/2021, Bvr‑26) and Influenza A/Vic, the active ingredients in Influsplit, are influenza virus vaccines presented as an injectable solution for intramuscular use. It is intended to prevent influenza infection caused by influenza A and B viruses in individuals for whom vaccination is indicated.

GNH USA supplies Influsplit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influsplit is a seasonal influenza vaccine used to stimulate immunity against influenza A and B viruses.

- Seasonal influenza: reduces the risk of infection and severe disease. - Influenza outbreaks: provides protection during community outbreaks. - High‑risk populations (e.g., elderly, chronic disease patients): lowers incidence of flu‑related complications.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Fever: low‑grade temperature rise within 24‑48 hours. - Headache or muscle aches: transient systemic symptoms.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder with muscle weakness. - High fever or seizures: uncommon but potentially serious systemic reactions.

Influsplit should be administered with consideration of the following precautions.

- Screen for severe allergy: assess history of hypersensitivity to vaccine components. - Delay vaccination: postpone in individuals with moderate or severe acute illness. - Pregnancy considerations: safety not established; weigh benefits and risks before use. - Concurrent immunizations: avoid administering live vaccines within 4 weeks. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Influsplit may interact with other therapies; monitor as indicated.

Major Interactions (Avoid): - Immunoglobulin therapy: may reduce vaccine efficacy. - Blood products: may interfere with immune response. - Live viral vaccines: avoid co‑administration within 4 weeks.

Moderate Interactions (Monitor Closely): - Antipyretics: may mask post‑vaccination fever. - Immunosuppressive drugs: may diminish antibody response. - Antihistamines: may lessen local reaction but are not contraindicated.